Brean Capital just initiated coverage of HZNP with a “buy” rating, and MEI beat earnings estimates by nineteen cents last quarter.
Horizon Pharma PLC (HZNP)
from US Investment Report
I’d like to remind 2015 investors to “take deep breaths” and think twice before mindlessly dumping stocks—as they did in January and again in the past week—at the prospect that the Fed might soon begin nudging up interest rates from the zero-level for the first time in six years.
It’s going to happen, whether in June or September, so accept it for what it is—a return to normalcy. And it seems clear that the Fed under Chairwoman Janet Yellen isn’t going to lift rates to anything approaching ruinous levels. Once it starts to happen, and investors realize that short rates of 1% or 2% aren’t the end of the world, stocks growing earnings at 15% a year and up will remain the best place to earn consistently favorable returns.
Based in Dublin, Horizon Pharma PLC (HZNP) specializes in treatments for arthritis, pain and inflammatory diseases. The stock has shot from 13 to 20 since December, but with analyst coverage doubling from 4 to 9 in the past month, and earnings growth of 26% a year, a target price of 27 is reasonable.
Stephen Quickel, U.S. Investment Report www.usinvestmentreport.com, 215-862-0399, March 13, 2015